Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Weight Watchers has outlasted diet fads, rebrands and even logic. But this time, it’s not carbs or keto that brought it down ...

As demand soared for weight-loss drugs, price signals worked.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment, with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

Scientifically Designed 4-Stage Fat Loss Supplement Offers Safe, Non-Prescription Alternative to GLP-1 Drugs Like ...

Eli Lilly (NYSE:LLY) shares climbed ~14% in the premarket on Thursday after the company said its oral GLP-1 receptor agonist ...

Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.

Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill. Supreme Court declines to hear Trump donor's challenge to ...